Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

SB 1092Sesión 2026

Qué cambió entre versiones

11 párrafos cambiaron+4 palabras agregadas−29 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

Florida Senate

-

ENROLLED

2026

Legislature

CS for CS for SB 1092

By

the Appropriations Committee on Health and Human Services;

the Committee on Health Policy; and Senator Massullo

603-02960-26 20261092c2

1 A bill to be entitled

20261092er

1

2 An act relating to podiatric medicine; amending s.

416 párrafos sin cambios

3 461.007, F.S.; requiring certain podiatric physicians,

4 instead of all podiatric physicians, to complete

5 specified continuing education; creating s. 461.011,

6 F.S.; providing legislative findings and intent;

7 defining terms; authorizing podiatric physicians to

8 perform procedures using cellular or tissue-based

9 products not approved by the United States Food and

10 Drug Administration under certain circumstances;

11 specifying requirements for the cellular or tissue

12 based products that may be used by such podiatric

13 physicians; requiring such podiatric physicians to

14 include a specified notice in any form of

15 advertisement; specifying requirements for such

16 notice; requiring podiatric physicians to obtain a

17 signed consent form from the patient or his or her

18 representative before performing procedures using

19 cellular or tissue-based products; specifying

20 requirements for the consent form; providing

21 applicability; providing for disciplinary action;

22 providing criminal penalties; authorizing the Board of

23 Podiatric Medicine to adopt rules; providing an

24 effective date.

25

26 Be It Enacted by the Legislature of the State of Florida:

27

28 Section 1. Subsection (3) of section 461.007, Florida

29 Statutes, is amended to read:

30 461.007 Renewal of license.—

31 (3) The board may by rule prescribe continuing education,

32 not to exceed 40 hours biennially, as a condition for renewal of

33 a license, with a minimum of 2 hours of continuing education

34 related to the safe and effective prescribing of controlled

35 substances

for licensees who are registered with the United

36

States Drug Enforcement Administration and authorized to

37

prescribe controlled substance pursuant to 21 U.S.C. s. 822

. The

38 criteria for such programs or courses shall be approved by the

39 board.

40 Section 2. Section 461.011, Florida Statutes, is created to

41 read:

42

461.011

Cellular and tissue-based products

.—

43

(1) The Legislature recognizes the significant potential of

44

c

ellular and tissue-based products

in advancing medical

45

treatments and improving patient outcomes and further recognizes

46

the need to ensure that such t

reatments

are provided using

47

cellular

or

tissue-based products

obtained in an ethical manner

48

that does not involve cells derived from aborted fetuses. It is

49

the intent of the Legislature to foster medical innovation while

50

upholding ethical standards that respect the sanctity of life.

51

By encouraging the use of cellular or tissue-based products, the

52

state will advance regenerative medicine in a manner consistent

53

with the values of th

e

state.

54

(2) As used in this section, the term:

55

(a) “

C

ellular or tissue-based products” means

products

56

containing or consisting of human cells or tissues

which

are

57

intended for implantation, transplantation, infusion, or

58

transfer into a human recipient. The term does not include:

59

1. Vascularized human organs for transplantation;

60

2. Whole blood or blood components or blood derivative

61

products;

62

3. Secreted or extracted human products, such as milk,

63

collagen, and cell factors, other than semen;

64

4. Minimally manipulated bone marrow for homologous use and

65

not combined with another article other than water,

66

crystalloids, or a sterilizing, preserving, or storage agent, if

67

the addition of the agent does not raise new clinical safety

68

concerns with respect to the bone marrow;

69

5. Ancillary products used in the manufacture of human

70

cells, tissues, or cellular or tissue-based products;

71

6. Cells, tissues, and organs derived from animals;

72

7. In vitro diagnostic products;

73

8. Blood vessels recovered with an organ which are intended

74

for use in organ transplantation and labeled “For use in organ

75

transplantation only”

; or

76

9.

Harvesting and reimplantation of autologous tissue

.

77

(b) “Minimally manipulated” means:

78

1. For structural tissue, processing that does not alter

79

the original relevant characteristics of the tissue relating to

80

the tissue’s utility for reconstruction, repair, or replacement.

81

2. For cells or nonstructural tissues, processing that does

82

not alter the relevant biological characteristics of cells or

83

tissues.

84

(c)

“

Procedure using cellular or tissue-based products

”

85

means a treatment involving the use of human cells, tissues, or

86

cellular or tissue-based products which complies with the

87

regulatory requirements provided in this section. The term does

88

not include treatment or research using human cells or tissues

89

derived from a fetus or an embryo after an abortion.

90

(3)(a)

A podiatric physician may perform

a procedure using

91

cellular or tissue-based products

that

are

not approved by the

92

United States Food and Drug Administration if such

products are

93

used for treatment or procedures within the scope of practice

94

for such podiatric physician and the

treatment or procedures

are

95

related to

connective tissue, ligament, and tendon repair;

wound

96

care

;

or pain management.

97

(b)

To ensure that the retrieval, manufacture, storage, and

98

use of

any cellular or tissue-based products pursuant to

this

99

section meet the highest standards, any

cellular or tissue-based

100

products

used by a podiatric physician for

a procedure

provided

101

under this section must meet all of the following conditions:

102

1.

Be retrieved, manufactured, and stored in a facility

103

that is registered and regulated by the United States Food and

104

Drug Administration.

105

2.

Be retrieved, manufactured, and stored in a facility

106

that is certified or accredited by one of the following

107

entities:

108

a.

The National Marrow Donor Program.

109

b.

The World Marrow Donor Association.

110

c.

The Association for the Advancement of Blood and

111

Biotherapies.

112

d.

The American Association of Tissue Banks.

113

3.

Contain viable or live cells upon post-thaw analysis and

114

be included in a post-thaw viability analysis report for the

115

product lot

,

which

must

be sent to the podiatric physician

116

before use with the podiatric physician’s patient.

117

(

4

)(a)

A podiatric physician who

performs a procedure using

118

cellular or tissue-based products

pursuant to this section shall

119

include the following in any form of advertisement:

120

121

THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW.

122

This podiatric physician performs

procedures using

123

cellular or tissue-based products

that have not yet

124

been approved by the United States Food and Drug

125

Administration. You are encouraged to consult with

126

your primary care provider before undergoing any

127

procedure using these products

.

128

129

(b)

The notice required under paragraph (a) must be clearly

130

legible and in a type size no smaller than the largest type size

131

used in the advertisement.

132

(

5

)(a)

A podiatric physician who

performs

a procedure

using

133

cellular or tissue-based products

pursuant to this section shall

134

obtain a signed consent form from the patient before performing

135

the

procedure

.

136

(b)

The consent form must be signed by the patient or, if

137

the patient is not legally competent, the patient’s

138

representative

,

and must state all of the following in language

139

the patient or his or her representative may reasonably be

140

expected to understand:

141

1.

The nature and character of the proposed treatment.

142

2.

That the proposed

procedure uses cellular or tissue

143

based products that have

not yet been approved by the United

144

States Food and Drug Administration.

145

3.

The anticipated results of the proposed treatment.

146

4.

The recognized serious possible risks, complications,

147

and anticipated benefits involved in the treatment and in the

148

recognized possible alternative forms of treatment, including

149

nontreatment.

150

5.

That the patient is encouraged to consult with his or

151

her primary care provider before undergoing

the procedure

.

152

(

6

)

This section does not apply to the following:

153

(a)

A podiatric physician who has obtained approval for an

154

investigational new drug or device from the United States Food

155

and Drug Administration for the use of human cells, tissues, or

156

cellular or tissue-based products; or

157

(b)

A podiatric physician who performs procedure

s

us

ing

158

cellular or tissue-based products

under an employment or other

159

contract on behalf of an institution certified or accredited by

160

any of the following:

161

1.

The Foundation for the Accreditation of Cellular

162

Therapy.

163

2.

The Blood and Marrow Transplant Clinical Trials Network.

164

3.

The Association for the Advancement of Blood and

165

Biotherapies.

166

(7)

A violation of this section may subject the podiatric

167

physician to disciplinary action by the board.

168

(8)

A podiatric physician who willfully performs, or

169

actively participates in, the following commits a felony of the

170

third degree, punishable as provided in s. 775.082, s. 775.083,

171

or s. 775.084, and is subject to disciplinary action under this

172

chapter and s. 456.072:

173

(a)

Treatment or research using human cells or tissues

174

derived from a fetus or an embryo after an abortion; or

175

(b)

The sale, manufacture, or distribution of computer

176

products created using human cells, tissues, or cellular or

177

tissue-based products.

178

(9)

The board may adopt rules necessary to implement this

179

section.

180 Section 3. This act shall take effect upon becoming a law.

Volver al texto completo